Meta Information

ID:procyanidin-c1

Name:Procyanidin C1

Schema Version:1.5

Alternate Names

• PCC1

Active Compound

Procyanidin C1

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:dietary_supplement

Indication

Focus:

healthspan

Description:

Targeting and eliminating senescent cells to potentially reverse or delay age-related pathologies and extend healthspan.

Typical Protocol

• No established human protocols exist for purified PCC1 as a senolytic agent.
• Preclinical mouse studies used intravenous doses, with oral bioavailability and efficacy being unconfirmed.
• PCC1 is a component of supplements like grape seed extract, but dosages of the specific C1 dimer are unstandardized.

Expected Cost Mean

Low Cost:

20

High Cost:

50

Cost Type:

monthly

Description:

Cost for high-quality grape seed extracts, which contain PCC1 among other procyanidins.

Summary

Procyanidin C1 is a plant-derived flavonoid identified as a potent senolytic, a compound that selectively induces apoptosis (cell death) in senescent cells. By clearing these dysfunctional, pro-inflammatory cells, PCC1 has been shown in animal models to improve physical function, reduce age-related disease burden, and extend lifespan. Its mechanism is thought to involve inhibiting key pro-survival pathways that senescent cells uniquely depend on.

Purpose

A plant-derived flavonoid that acts as a senolytic to clear aging cells.

Card Summary

A potent, naturally-derived senolytic that selectively eliminates senescent cells, showing promise in preclinical models for reversing age-related dysfunction.

Drug Class

null

Drugs In Class

Empty Array

Impact

Score:

3.8

Justification:

Potent senolytic with lifespan extension in mice, but lacks any human trial data.

Evidence

Grade:

C

Score:

3

Justification:

Strong in-vitro and mouse model data, but currently no human clinical trials.

Safety

Score:

4.5

Justification:

Unknown safety profile in humans for purified, high-dose use as a senolytic.

Flags

• No human safety or efficacy data exists for purified PCC1 as a senolytic.
• Not commercially available as a pure compound; only as a component of extracts.
• The effective senolytic dose, frequency, and oral bioavailability in humans are unknown.
• Extracts containing PCC1 may interact with anticoagulant or antiplatelet medications.

Verdict

A highly promising preclinical senolytic, but entirely unproven in humans.

Created

2026-05-06T16:38:16.447808Z

Ai Model

Gemini 2.5 Pro (High)